Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 12949

1.

Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report.

Lichtenstein GR, Feagan BG, Mahadevan U, Salzberg BA, Langholff W, Morgan GJ, Safdi M, Nissinen R, Taillard F, Sandborn WJ, Cohen RD.

Am J Gastroenterol. 2018 Jul 19. doi: 10.1038/s41395-018-0202-9. [Epub ahead of print]

PMID:
30022113
2.

Cost of biologic treatment persistence or switching in rheumatoid arthritis.

Gu T, Mutebi A, Stolshek BS, Tan H.

Am J Manag Care. 2018 Jul;24(8 Spec No.):SP338-SP345.

3.

Two-year adherence and costs for biologic therapy for rheumatoid arthritis.

Stolshek BS, Wade S, Mutebi A, De AP, Wade RL, Yeaw J.

Am J Manag Care. 2018 Jul;24(8 Spec No.):SP315-SP321.

4.

Low Discontinuation Rate of Infliximab Treatment in Steroid-Dependent/Refractory Crohn's Disease Patients.

Kaymak T, Moriconi F, Niess JH, Beglinger C, Hruz P.

Inflamm Intest Dis. 2018 Mar;2(3):171-179. doi: 10.1159/000486676. Epub 2018 Feb 21.

PMID:
30018967
5.

The Efficacy and Safety of Golimumab as Third- or Fourth-Line Anti-TNF Therapy in Patients with Refractory Crohn's Disease: A Case Series.

Russi L, Scharl M, Rogler G, Biedermann L.

Inflamm Intest Dis. 2017 Nov;2(2):131-138. doi: 10.1159/000481400. Epub 2017 Oct 19.

PMID:
30018964
6.
7.

CME Part II Psoriasis: Which Therapy for Which Patient Focus on special populations and chronic infections.

Kaushik SB, Lebwohl MG.

J Am Acad Dermatol. 2018 Jul 11. pii: S0190-9622(18)32214-X. doi: 10.1016/j.jaad.2018.06.056. [Epub ahead of print] Review.

PMID:
30017706
8.

CME Part I Psoriasis: Which Therapy for Which Patient Psoriasis comorbidities and preferred systemic agents.

Kaushik SB, Lebwohl MG.

J Am Acad Dermatol. 2018 Jul 11. pii: S0190-9622(18)32215-1. doi: 10.1016/j.jaad.2018.06.057. [Epub ahead of print] Review.

PMID:
30017705
9.

Nocardiosis in a patient with anti-PD-1-associated colitis treated with infliximab.

Glutsch V, Gesierich A, Goebeler M, Forster J, Schilling B.

Eur J Cancer. 2018 Jul 12. pii: S0959-8049(18)30906-7. doi: 10.1016/j.ejca.2018.06.014. [Epub ahead of print] No abstract available.

PMID:
30017385
10.

Highlights of Skin Disease Education Foundations 42nd Annual Hawaii Dermatology Seminar.

Baldwin HE, Stein Gold LF, Gordon KB, Green JB, Leonardi CL, Sengelmann RD.

Semin Cutan Med Surg. 2018 Jun;37(4S):S75-S84. doi: 10.12788/j.sder.2018.031.

PMID:
30016379
11.

Clinically important neutralizing anti-drug antibodies detected with an in-house competitive ELISA.

Ogrič M, Žigon P, Lakota K, Praprotnik S, Drobne D, Štabuc B, Sodin-Semrl S, Čučnik S.

Clin Rheumatol. 2018 Jul 16. doi: 10.1007/s10067-018-4213-0. [Epub ahead of print]

PMID:
30014359
12.

The Continental Divide: Anti-TNF Use in Pediatric IBD Is Different in North America Compared to Other Parts of the World.

Church PC, Hyams J, Ruemmele F, de Ridder L, Turner D, Griffiths AM.

Can J Gastroenterol Hepatol. 2018 Jun 12;2018:3190548. doi: 10.1155/2018/3190548. eCollection 2018.

13.

TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn's disease patients?

Verstockt B, Verstockt S, Blevi H, Cleynen I, de Bruyn M, Van Assche G, Vermeire S, Ferrante M.

Gut. 2018 Jul 14. pii: gutjnl-2018-316845. doi: 10.1136/gutjnl-2018-316845. [Epub ahead of print] No abstract available.

PMID:
30007919
14.

Effects of tumor necrosis factor-α, interleukin-23 and interleukin-17A inhibitors on bodyweight and body mass index in patients with psoriasis.

Takamura S, Takahashi A, Inoue Y, Teraki Y.

J Dermatol. 2018 Jul 13. doi: 10.1111/1346-8138.14526. [Epub ahead of print]

PMID:
30004583
15.

Role of interstitial fluid turnover on target suppression by therapeutic biologics using a minimal physiologically-based pharmacokinetic (mPBPK) model.

Li X, Jusko W, Cao Y.

J Pharmacol Exp Ther. 2018 Jul 12. pii: jpet.118.250134. doi: 10.1124/jpet.118.250134. [Epub ahead of print]

16.

Infliximab.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

17.

Survival and safety of infliximab bio-original and infliximab biosimilar (CT-P13) in usual rheumatology care.

Nikiphorou E, Hannonen P, Asikainen J, Borodina J, Kokko A, Paalanen K, Rannio T, Sokka T.

Clin Exp Rheumatol. 2018 Jun 7. [Epub ahead of print]

PMID:
29998827
18.

Long term treatment with infliximab in pediatric Vogt-Koyanagi-Harada disease.

Budmann GA, Franco LG, Pringe A.

Am J Ophthalmol Case Rep. 2018 Jul 2;11:139-141. doi: 10.1016/j.ajoc.2018.06.022. eCollection 2018 Sep.

19.

Treatment of chronic inflammatory rheumatism by biotherapy in Gabon : eligibility and follow-up of the first 8 patients in sub-Saharan Africa.

Missounga L, Iba Ba J, Nseng Nseng Ondo IR, Nziengui Madjinou MIC, Mwenpindi Malekou D, Mouendou Mouloungui EG, Boguikouma JB.

Med Sante Trop. 2018 May 1;28(2):197-200. doi: 10.1684/mst.2018.0781.

20.

Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database.

Sruamsiri R, Iwasaki K, Tang W, Mahlich J.

BMC Dermatol. 2018 Jul 11;18(1):5. doi: 10.1186/s12895-018-0074-0.

Supplemental Content

Loading ...
Support Center